e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19.9m and future tax credits of c £6m, along with a reduction in cash burn, should fund ETX through to 2019. Legacy assets ETS6103 and ETS2101 will continue to be wound down with reduced costs; the company will look to out-license both. Validation of the platform is key to driving value an
20 Sep 2016
Focused on value creation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Focused on value creation
e-Therapeutics plc (ETX:LON) | 10.0 0 0.8% | Mkt Cap: 58.6m
- Published:
20 Sep 2016 -
Author:
Lala Gregorek -
Pages:
4
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19.9m and future tax credits of c £6m, along with a reduction in cash burn, should fund ETX through to 2019. Legacy assets ETS6103 and ETS2101 will continue to be wound down with reduced costs; the company will look to out-license both. Validation of the platform is key to driving value an